Seasonal fluctuations in revenue and profit
First written in FY2020. 3 of 8 entries say "Mitigated", first in FY2025. Latest entry: 2026-08-05.
Jmdc moved to the "Worse" side of this theme in 2023, 1 year before the typical company in this theme (2024).
The whole theme swung hardest in 2017: 2 of 8 companies on the "Worse" side.
5 other companies' latest entry also says "Restated".
- FY2026MitigatedAnnual report
「Segment profit (¥ million) 4,800 6,922 11,722 / Share (%) 41.0 59.0 100.0」
Although Health Big Data segment profit remained concentrated in the second half, the second half's share decreased from 60.7% in the previous fiscal year to 59.0%, easing the numerical intensity of the seasonal concentration. - FY2025MitigatedAnnual report
「Segment profit (¥ million) Share (%) 3,751 39.3 5,805 60.7 100.0」
Although Health Big Data segment profit remained concentrated in the second half, the second half's share decreased from 68.4% in the previous fiscal year to 60.7%. The numerical intensity of the seasonal concentration has eased. - FY2024WorsenedAnnual report
「For the fiscal year ended March 2024, the first and second halves accounted for 39.2% and 60.8% of Health Big Data segment revenue, respectively, and 31.6% and 68.4% of segment profit, respectively.」
Revenue and profit remained concentrated in the second half, with the second half's share of profit increasing from 67.0% to 68.4%. - FY2023WorsenedAnnual report
「Meanwhile, because our data business has a predominantly fixed-cost structure, profit is consequently subject to seasonal concentration in the second half of the fiscal year.」
For the fiscal year ended March 2023, the first and second halves accounted for 41.1% and 58.9% of Health Big Data revenue, respectively, and 33.0% and 67.0% of segment profit, respectively, indicating a stronger concentration of profit in the second half than in the previous year. - FY2022RestatedAnnual report
「Because our data business has a predominantly fixed-cost structure, profit is consequently subject to seasonal concentration in the second half of the fiscal year.」
The risk of concentration in the second half is reiterated. For the fiscal year ending March 2022, the first and second halves accounted for 41.6% and 58.4% of revenue, respectively, and 35.7% and 64.3% of segment profit, respectively. - FY2020First statedAnnual report
「Demand for our ad hoc data sales service, which extracts and analyzes the data required for individual requests from a database for pharmaceutical companies, research institutions, and life and non-life insurance companies, tends to increase toward the second half of the fiscal year.」
The risk of profit concentration in the second half due to a predominantly fixed-cost structure is described. In the fiscal year ended March 2020, the second half accounted for 58.7% of revenue and 67.0% of segment profit.